Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04301661 · ClinicalTrials.gov registry record
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 25
- Enrollment target
NCT04301661 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 25 participants.
The verdict
NCT04301661 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This study will evaluate the intracellular pharmacokinetics and platelet effects of abacavir (ABC), lamivudine (3TC), tenofovir alafenamide (TAF), and emtricitabine (FTC) in persons living with HIV that are receiving these medications as part of standard HIV care. Participants remaining on ABC/3TC- or TAF/FTC-containing therapy will be on study for 4 weeks, and will have two visits: a screening visit and one short PK visit consisting of a single blood draw at week 4. Participants switching from their ABC/3TC-containing therapy will be on study for 3 weeks, and will have nine visits: a screening visit and 8 short PK visits consisting of a single blood draw at Day 0, 1, 3, 7, 10, 14, 18, and 21.
Interventions
- OTHER Blood collection
- DRUG Switch
- DRUG Tenofovir alafenamide/emtricitabine
- DRUG Abacavir/lamivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-03-06 |
| Est. Completion | 2021-12-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04301661
The ClinicalTrials.gov registry entry for NCT04301661 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Blood collection is the first listed.
NCT04301661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04301661 about?
NCT04301661 is a clinical study titled "Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites". This study will evaluate the intracellular pharmacokinetics and platelet effects of abacavir (ABC), lamivudine (3TC), tenofovir alafenamide (TAF), and emtricitabine (FTC) in persons living with HIV that are receiving these medications as part of standard HIV care. Participants remaining on ABC/3TC-...
What is the current status of trial NCT04301661?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2020-03-06. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT04301661?
The interventions under investigation include: Blood collection (OTHER), Switch (DRUG), Tenofovir alafenamide/emtricitabine (DRUG), Abacavir/lamivudine (DRUG).
Who is sponsoring clinical trial NCT04301661?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.